Pneumovax 23
Details for Pneumovax 23 vaccine and its components.
Sponsor:
Merck Sharp & Dohme (Australia)
Administration route:
Intramuscular injection, Subcutaneous injection
Vaccine group:
Pneumococcal polysaccharide vaccine
Registered for use in children aged ≥2 years and in adults.
23vPPV — 23-valent pneumococcal polysaccharide vaccine
Each 0.5 mL monodose vial contains:
- 25 µg each of pneumococcal capsular polysaccharide of serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F and 33F
- 0.25% phenol
For detailed advice on vaccine dosage, administration, contraindications and precautions, please visit the relevant disease chapter.
Page history
Last updated:
4 June 2018
Last reviewed:
4 June 2018
Definitions
- 23vPPV
- 23-valent pneumococcal polysaccharide vaccine
Printed content may be out of date. For up to date information, always refer to the digital version: https://immunisationhandbook.health.gov.au/vaccines/pneumovax-23.